Monday, August 4, 2025

Latest

Compass Pathways To Start Phase II Trial For Psilocybin PTSD Therapy

Compass Pathways (Nasdaq: CMPS) this morning announced that it will be launching the phase II clinical trial for its synthetic psilocybin compound known as COMP360. The trial aims to assess the safety and tolerability of psilocybin therapy in treating post-traumatic stress disorder.

COMP360 is the firm’s proprietary formulation of synthetic psilocybin currently being developed for treatment-resistant depression.

The multicentre, open-label trial will enroll 20 participants and will focus on the safety and tolerability of psilocybin therapy in people with PTSD stemming from trauma experienced as an adult. Participants will receive a single 25mg dose of COMP360, combined with psychological support and therapy protocols, and will be followed up for 12 weeks.

“We have made great progress in developing COMP360 psilocybin therapy for patients suffering [from] treatment-resistant depression, and are pleased to be able to expand development into the indication of PTSD, another area of significant unmet need. As many as one in 20 people in the UK suffer [from] PTSD and up to 40% of those are not helped by existing treatments,” said Compass Pathways CEO George Goldsmith.

The study is set to commence at The Institute of Psychiatry, Psychology & Neuroscience at King’s College London.

Compass Pathways last traded at US$44.86 on the Nasdaq.


Information for this briefing was found via Edgar and Compass Pathways. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

San Dimas: First Majestic Silver’s Sleeper Asset

New Gold Q2 Earnings: Record Free Cash Flow

STLLR Gold: The Tower Gold PEA

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Compass Pathways Closes Enrollment For Phase IIb Psilocybin Clinical Trial

Compass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the...

Monday, June 28, 2021, 07:37:00 AM

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Compass Pathways Sees “Reduction In Depressive Symptom” In Phase IIb Psilocybin Clinical Trial

Compass Pathways (Nasdaq: CMPS) announced today that its phase IIb clinical trial of COMP360 psilocybin therapy...

Tuesday, November 9, 2021, 12:33:00 PM

Psychedelics & The Need For Digital Therapeutic Solutions In Treating Mental Health

In terms of investment dollar inflows, one of the largest focuses of 2020 has arguably...

Sunday, November 1, 2020, 09:00:00 AM

Andrew Left’s Citron Research Places $100 Price Target On Compass Pathways

Andrew Left of Citron Research today released a research paper on Compass Pathways (NASDAQ: CMPS),...

Monday, October 5, 2020, 07:01:00 PM